Opens in a new window Opens an external website Opens an external website in a new window
This website utilizes technologies such as cookies to enable essential site functionality, as well as for analytics, personalization, and targeted advertising. Privacy Policy
Main content starts here
ScienceInsider
People & Events
ET
Psychiatrist Daniel Amen (left), who runs a chain of mental health care clinics, could soon join the board that advises the National Institute of Mental Health.Michael Tullberg/Getty Images
President Donald Trump’s administration plans to appoint celebrity psychiatrist Daniel Amen to the advisory council of the National Institute of Mental Health (NIMH), Science has learned. Amen’s pending appointment adds to signs that Health and Human Services (HHS) Secretary Robert F. Kennedy Jr. is trying to reshape the $2.2 billion research institute to align it more closely with his Make America Healthy Again (MAHA) movement.
Amen is CEO of a chain of 12 clinics that use costly brain scanning technology to aid in diagnosing mental illnesses such as depression, attention-deficit/hyperactivity disorder, and post-traumatic stress disorder (PTSD)—an approach some neuroscientists question. He confirmed the nomination in an email to Science and said he would be “honored to serve” on the National Advisory Mental Health Council (NAMHC), which weighs in on funding initiatives and performs a second layer of peer review for grants.
A person with knowledge of the situation said Amen was not on a list of potential council members recommended by NIMH staff, but was put forward by HHS. His appointment is currently pending ethics clearance.
Amen has written more than 30 books, including 13 New York Times bestsellers, and produced several TV series about how factors such as exercise, diet, breathing techniques, and focus contribute to brain health. He has appeared at various MAHA events and told Science he is working with Kennedy and the White House Faith Office on brain-health–related projects across the government.
One NIMH staffer who asked not to be identified called Amen’s pending appointment “very frustrating as it’s clear this administration does not take mental illness seriously. Every week is more disappointing news.” Amen has never himself had a National Institutes of Health (NIH) grant, but says his clinical experience could help guide research and generate insights.
Amen’s approach involves a brain-imaging technology called single photon emission computed tomography (SPECT), which uses injected radioisotopes to measure blood flow in the brain. It is generally used to diagnose conditions such as stroke damage and epilepsy, not psychiatric disorders. This type of imaging can cost thousands of dollars and, because regulators have not approved it for psychiatric applications, it is not typically covered by insurance.
Amen Clinics has collected hundreds of thousands of SPECT images, along with patient health data, and published several studies suggesting the imaging improves diagnosis in PTSD and other conditions. He says this work has revealed that “most psychiatric illnesses are not primarily mental health issues, rather they are brain health issues that steal people’s minds.”
Other research groups, including an NIH-supported, international consortium called ENIGMA that looks for links between genetics and brain structure in psychiatric illness, have used Amen’s SPECT data in retrospective analyses, often in combination with other imaging methods. (Amen says about 95% of his patients sign consent forms allowing their scans and health data to be used in any future research.)
Vince Calhoun, an engineer and neuroscientist at Georgia State University who has collaborated with Amen on several papers, says the SPECT database has been valuable in showing how brain networks change in mental illness. He’s happy to see NAMHC’s roster include someone who works with quantitative neuroimaging measures.
But other experts have criticized Amen’s use of SPECT in his clinics, saying the technology has not been sufficiently tested in prospective clinical trials. A 2012 consensus statement from the American Psychiatric Association (APA) concluded that imaging biomarkers are not clinically useful for diagnosis. A more recent paper from APA-associated scientists says biomarkers should be included in the manual that psychiatrists use to make diagnoses, although it does not specifically mention SPECT.
Neurologist Helen Mayberg of the Icahn School of Medicine at Mount Sinai says Amen is “a curious choice” for NAMHC. She says she is “lock, stock” with Amen on the idea that brain imaging will eventually yield useful diagnostic information about psychiatric disorders, but says developing such markers and proving they work has proved extremely difficult. “He has a lived experience of using tools toward this end, but hasn’t done the science to show which part is valid or not,” she says.
Others were more critical. Psychiatrist Joshua Gordon, former NIMH director, says Amen’s “chain of clinics exploits desperate patients and treats them based on tests that require delivery of radioactive materials without clear evidence of benefit. There is no advisory board in the world I would want him to be on, much less the council that advises the largest and most important funder of mental health research in the world.”
Amen says his clinics do not make diagnoses based on SPECT imaging, but use the images as a way to understand how an individual brain is functioning and guide treatment decisions. He adds that he is not “wed to SPECT” and wants to use any imaging technology that proves useful.
NIMH has been without a permanent director since Gordon left in June 2024 for Columbia University. Last month, Science reported that Kennedy overrode NIH Director Jay Bhattacharya’s recommendation of neuroscientist Vikaas Sohal of the University of California (UC) San Francisco for the position. Instead, Kennedy planned to appoint a MAHA-aligned candidate, Stanford University psychiatrist Shebani Sethi, who studies dietary modifications as a treatment for mental illnesses. Sethi’s appointment has not yet been announced.
Amen is the third MAHA-aligned member appointed this year to NAMHC. The Trump administration’s only previous appointments are two prominent skeptics of antidepressants: Laura Delano, founder of the nonprofit Inner Compass Initiative, and UC Los Angeles social scientist David Cohen.
If his appointment is finalized, Amen says he hopes to work with NIMH on “developing objective measures that help us understand why treatments work and for whom. I would also like to advance rigorous research into the appropriate clinical use of neuroimaging in complex psychiatric cases.”
doi: 10.1126/science.zjvj2kk
People & Events
Trump administration
Sara Reardon is a staff writer based in Boston, where she covers biomedical research and policy. She can be found on Signal at sara\_reardon.59
Can researchers bring order to the confusing world of AI ‘benchmarks’?
By
Ananya
To deter bioterrorism, U.S. imposes new rules on ordering synthetic DNA
By
Phie Jacobs
Researchers sue to block NSF from demolishing social science directorate
Amid the unprecedented upheaval in U.S. science, hard-hitting, trustworthy reporting has never been more important. As part of the AAAS mission, Science has built a global award-winning network of reporters and editors that independently cover the most important developments in research and policy.
Your tax-deductible contribution plays a critical role in sustaining this effort.
If, at any time, you would like to stop or make changes to your monthly gift, please contact the Philanthropy Office at philanthropy@aaas.org or 202-326-6636.
Help News from Science publish trustworthy, high-impact stories about research and the people who shape it. Please make a tax‑deductible gift today.